Nisa Investment Advisors LLC Grows Stock Position in Axonics, Inc. (NASDAQ:AXNX)

Nisa Investment Advisors LLC increased its stake in Axonics, Inc. (NASDAQ:AXNXGet Rating) by 14.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,620 shares of the company’s stock after acquiring an additional 200 shares during the period. Nisa Investment Advisors LLC’s holdings in Axonics were worth $92,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Assetmark Inc. lifted its position in Axonics by 21.2% in the second quarter. Assetmark Inc. now owns 71,617 shares of the company’s stock valued at $4,059,000 after purchasing an additional 12,506 shares during the last quarter. Mount Yale Investment Advisors LLC boosted its position in Axonics by 31.6% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 4,395 shares of the company’s stock valued at $249,000 after buying an additional 1,056 shares during the period. US Bancorp DE grew its holdings in Axonics by 432.4% in the 2nd quarter. US Bancorp DE now owns 13,353 shares of the company’s stock worth $757,000 after acquiring an additional 10,845 shares during the last quarter. Chartwell Investment Partners LLC increased its position in shares of Axonics by 2.6% in the second quarter. Chartwell Investment Partners LLC now owns 49,672 shares of the company’s stock valued at $2,815,000 after acquiring an additional 1,242 shares during the period. Finally, Calamos Advisors LLC raised its stake in shares of Axonics by 4.5% during the second quarter. Calamos Advisors LLC now owns 71,406 shares of the company’s stock valued at $4,047,000 after acquiring an additional 3,066 shares during the last quarter. 98.88% of the stock is currently owned by hedge funds and other institutional investors.

Axonics Stock Down 1.2 %

Shares of NASDAQ AXNX opened at $61.47 on Tuesday. The company has a 50 day moving average of $70.97 and a 200 day moving average of $63.15. Axonics, Inc. has a twelve month low of $38.41 and a twelve month high of $79.92. The firm has a market cap of $2.90 billion, a P/E ratio of -37.25 and a beta of 0.42.

Axonics (NASDAQ:AXNXGet Rating) last announced its quarterly earnings results on Monday, October 31st. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. Axonics had a negative return on equity of 16.38% and a negative net margin of 31.35%. The firm had revenue of $70.38 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period in the prior year, the company posted ($0.38) earnings per share. The company’s quarterly revenue was up 50.0% on a year-over-year basis. As a group, equities analysts expect that Axonics, Inc. will post -1.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Piper Sandler boosted their price target on Axonics from $82.00 to $84.00 and gave the company an “overweight” rating in a report on Wednesday, October 5th. Truist Financial lifted their price target on shares of Axonics from $80.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, November 1st. Jefferies Financial Group began coverage on shares of Axonics in a research report on Wednesday, October 12th. They issued a “hold” rating and a $75.00 target price for the company. Wells Fargo & Company upped their target price on Axonics from $83.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, November 1st. Finally, Royal Bank of Canada initiated coverage on Axonics in a research note on Friday, October 21st. They issued an “outperform” rating and a $85.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $80.78.

Insider Transactions at Axonics

In related news, insider Danny L. Dearen sold 50,000 shares of the stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $70.89, for a total transaction of $3,544,500.00. Following the transaction, the insider now owns 8,156 shares in the company, valued at $578,178.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Danny L. Dearen sold 50,000 shares of the stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $70.89, for a total transaction of $3,544,500.00. Following the transaction, the insider now directly owns 8,156 shares of the company’s stock, valued at approximately $578,178.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Danny L. Dearen sold 656 shares of Axonics stock in a transaction on Tuesday, September 13th. The stock was sold at an average price of $75.60, for a total value of $49,593.60. Following the completion of the sale, the insider now directly owns 7,500 shares of the company’s stock, valued at approximately $567,000. The disclosure for this sale can be found here. Insiders sold 124,960 shares of company stock worth $8,851,749 over the last three months. 2.31% of the stock is currently owned by company insiders.

Axonics Profile

(Get Rating)

Axonics, Inc, a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention.

Read More

Institutional Ownership by Quarter for Axonics (NASDAQ:AXNX)

Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.